Reona Morio1, Michio Imamura1, Yoshiiku Kawakami1, Kei Morio1, Tomoki Kobayashi1, Satoe Yokoyama1, Yuki Kimura1, Yuko Nagaoki1, Tomokazu Kawaoka1, Masataka Tsuge1, Akira Hiramatsu1, C Nelson Hayes1, Hiroshi Aikata1, Shoichi Takahashi1, Daiki Miki2, Hidenori Ochi2, Nami Mori3, Shintaro Takaki3, Keiji Tsuji3, Kazuaki Chayama4,5. 1. Department of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. 2. Laboratory for Digestive Diseases, SNP Research Center, The Institute of Physical and Chemical Research (RIKEN), Hiroshima, Japan. 3. Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital, Hiroshima, Japan. 4. Department of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. chayama@hiroshima-u.ac.jp. 5. Laboratory for Digestive Diseases, SNP Research Center, The Institute of Physical and Chemical Research (RIKEN), Hiroshima, Japan. chayama@hiroshima-u.ac.jp.
Abstract
BACKGROUND: Daclatasvir and asunaprevir combination therapy has shown a high virological response for chronic genotype 1 hepatitis C virus (HCV)-infected patients. However, the safety and efficacy of the therapy for older patients are unknown. METHODS: One hundred seventy patients younger than 75 years and 139 patients aged 75 years or older with genotype 1 HCV infection were treated for 24 weeks with daclatasvir plus asunaprevir. Pretreatment drug-resistance-associated variants at NS5A-L31 and NS5A-Y93 were determined by the Invader assay. Virological response and adverse events according to age were analyzed. RESULTS: The sustained virological response (SVR) rate for older patients was similar to that for younger patients (97.1 and 92.4 % respectively). In multivariate regression analysis, prior simeprevir treatment (odds ratio 56.6 for absence; P < 0.001) was identified as a significant independent predictor of SVR. The SVR rate for patients with pretreatment resistance-associated variants (RAVs) at a low population frequency (less than 25 %) was similar to that for patients with no detectable RAVs. The frequency of adverse events was similar between younger and older patients. All 19 very elderly patients (85 years or older) completed the 24 weeks of treatment and achieved SVR. CONCLUSIONS: Older patients have a virological response and tolerance of daclatasvir plus asunaprevir therapy similar to those of younger patients. Even though RAVs were detected, virological response similar to that for patients with no detectable RAVs may still be expected for patients with RAVs as long as the population frequency is low.
BACKGROUND: Daclatasvir and asunaprevir combination therapy has shown a high virological response for chronic genotype 1 hepatitis C virus (HCV)-infected patients. However, the safety and efficacy of the therapy for older patients are unknown. METHODS: One hundred seventy patients younger than 75 years and 139 patients aged 75 years or older with genotype 1 HCV infection were treated for 24 weeks with daclatasvir plus asunaprevir. Pretreatment drug-resistance-associated variants at NS5A-L31 and NS5A-Y93 were determined by the Invader assay. Virological response and adverse events according to age were analyzed. RESULTS: The sustained virological response (SVR) rate for older patients was similar to that for younger patients (97.1 and 92.4 % respectively). In multivariate regression analysis, prior simeprevir treatment (odds ratio 56.6 for absence; P < 0.001) was identified as a significant independent predictor of SVR. The SVR rate for patients with pretreatment resistance-associated variants (RAVs) at a low population frequency (less than 25 %) was similar to that for patients with no detectable RAVs. The frequency of adverse events was similar between younger and older patients. All 19 very elderly patients (85 years or older) completed the 24 weeks of treatment and achieved SVR. CONCLUSIONS: Older patients have a virological response and tolerance of daclatasvir plus asunaprevir therapy similar to those of younger patients. Even though RAVs were detected, virological response similar to that for patients with no detectable RAVs may still be expected for patients with RAVs as long as the population frequency is low.
Authors: John G McHutchison; Eric J Lawitz; Mitchell L Shiffman; Andrew J Muir; Greg W Galler; Jonathan McCone; Lisa M Nyberg; William M Lee; Reem H Ghalib; Eugene R Schiff; Joseph S Galati; Bruce R Bacon; Mitchell N Davis; Pabak Mukhopadhyay; Kenneth Koury; Stephanie Noviello; Lisa D Pedicone; Clifford A Brass; Janice K Albrecht; Mark S Sulkowski Journal: N Engl J Med Date: 2009-07-22 Impact factor: 91.245
Authors: Tetsuro Shimakami; Christoph Welsch; Daisuke Yamane; David R McGivern; Minkyung Yi; Stefan Zeuzem; Stanley M Lemon Journal: Gastroenterology Date: 2010-11-04 Impact factor: 22.682
Authors: Anna S Lok; David F Gardiner; Christophe Hézode; Eric J Lawitz; Marc Bourlière; Gregory T Everson; Patrick Marcellin; Maribel Rodriguez-Torres; Stanislas Pol; Lawrence Serfaty; Timothy Eley; Shu-Pang Huang; Jianling Li; Megan Wind-Rotolo; Fei Yu; Fiona McPhee; Dennis M Grasela; Claudio Pasquinelli Journal: J Hepatol Date: 2013-10-26 Impact factor: 25.083
Authors: Seung Kak Shin; Jin Woo Lee; Hannah Ra; Oh Sang Kwon; Jong Beom Shin; Young Joo Jin; Sangheun Lee; Ki Jun Han; Young Nam Kim; Tae Hun Kim; Yun Soo Kim; Ju Hyun Kim Journal: J Korean Med Sci Date: 2019-10-28 Impact factor: 2.153